Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more
Celyad Oncology SA (CLYYF) - Net Assets
Latest net assets as of June 2025: $-3.10 Million USD
Based on the latest financial reports, Celyad Oncology SA (CLYYF) has net assets worth $-3.10 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.70 Million) and total liabilities ($8.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.10 Million |
| % of Total Assets | -54.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -152.01% |
| 10-Year Change | -114.46% |
| Growth Volatility | 153.59 |
Celyad Oncology SA - Net Assets Trend (2010–2024)
This chart illustrates how Celyad Oncology SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Celyad Oncology SA (2010–2024)
The table below shows the annual net assets of Celyad Oncology SA from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-16.12 Million | -355.71% |
| 2023-12-31 | $6.30 Million | +46.03% |
| 2022-12-31 | $4.32 Million | -90.11% |
| 2021-12-31 | $43.64 Million | +40.80% |
| 2020-12-31 | $30.99 Million | -32.06% |
| 2019-12-31 | $45.62 Million | -17.94% |
| 2018-12-31 | $55.59 Million | +16.94% |
| 2017-12-31 | $47.53 Million | -47.70% |
| 2016-12-31 | $90.88 Million | -18.47% |
| 2015-12-31 | $111.47 Million | +317.75% |
| 2014-12-31 | $26.68 Million | +57.91% |
| 2013-12-31 | $16.90 Million | +1387.54% |
| 2012-12-31 | $-1.31 Million | -256.22% |
| 2011-12-31 | $840.11K | -90.33% |
| 2010-12-31 | $8.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Celyad Oncology SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34350250000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.22 Million | % |
| Other Comprehensive Income | $339.86 Million | % |
| Total Equity | $-16.12 Million | 100.00% |
Celyad Oncology SA Competitors by Market Cap
The table below lists competitors of Celyad Oncology SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Total Metals Corp.
V:TT
|
$6.71 Million |
|
CHERRY SE O.N.
F:C3RY
|
$6.72 Million |
|
Charlie's Holdings Inc.
OTCQB:CHUC
|
$6.72 Million |
|
Banzai International Inc
NASDAQ:BNZI
|
$6.72 Million |
|
Magna Prima Bhd
KLSE:7617
|
$6.71 Million |
|
PT Jobubu Jarum Minahasa Tbk
JK:BEER
|
$6.71 Million |
|
PT UBC Medical Indonesia Tbk
JK:LABS
|
$6.71 Million |
|
Hapbee Technologies Inc
PINK:HAPBF
|
$6.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celyad Oncology SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,304,000 to -16,120,000, a change of -22,424,000 (-355.7%).
- Net loss of 5,824,000 reduced equity.
- Other comprehensive income increased equity by 8,133,000.
- Other factors decreased equity by 24,733,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.82 Million | -36.13% |
| Other Comprehensive Income | $8.13 Million | +50.45% |
| Other Changes | $-24.73 Million | -153.43% |
| Total Change | $- | -355.71% |
Book Value vs Market Value Analysis
This analysis compares Celyad Oncology SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $1.37 | $0.65 | x |
| 2011-12-31 | $0.13 | $0.65 | x |
| 2012-12-31 | $-0.21 | $0.65 | x |
| 2013-12-31 | $4.12 | $0.65 | x |
| 2014-12-31 | $3.95 | $0.65 | x |
| 2015-12-31 | $13.13 | $0.65 | x |
| 2016-12-31 | $9.74 | $0.65 | x |
| 2017-12-31 | $4.94 | $0.65 | x |
| 2018-12-31 | $4.99 | $0.65 | x |
| 2019-12-31 | $3.64 | $0.65 | x |
| 2020-12-31 | $2.22 | $0.65 | x |
| 2021-12-31 | $2.80 | $0.65 | x |
| 2022-12-31 | $0.19 | $0.65 | x |
| 2023-12-31 | $0.25 | $0.65 | x |
| 2024-12-31 | $-0.39 | $0.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celyad Oncology SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3131.18%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-186.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -77.22% | -442.68% | 0.09x | 2.01x | $-7.58 Million |
| 2011 | -1087.23% | -33915.05% | 0.00x | 8.19x | $-9.22 Million |
| 2012 | 0.00% | -25044.44% | 0.00x | 0.00x | $-13.39 Million |
| 2013 | -73.06% | 0.00% | 0.00x | 1.92x | $-14.04 Million |
| 2014 | -61.66% | -11269.18% | 0.00x | 1.65x | $-19.12 Million |
| 2015 | -26.12% | -970466.67% | 0.00x | 1.43x | $-40.26 Million |
| 2016 | -25.97% | -235.78% | 0.07x | 1.53x | $-32.69 Million |
| 2017 | -118.64% | -1593.08% | 0.05x | 1.63x | $-61.15 Million |
| 2018 | -67.33% | -1201.51% | 0.03x | 1.70x | $-42.99 Million |
| 2019 | -62.76% | -477200.00% | 0.00x | 1.97x | $-33.19 Million |
| 2020 | -55.51% | -344080.00% | 0.00x | 2.13x | $-20.30 Million |
| 2021 | -60.75% | 0.00% | 0.00x | 1.83x | $-30.88 Million |
| 2022 | -948.23% | 0.00% | 0.00x | 4.57x | $-41.37 Million |
| 2023 | -134.01% | -8282.35% | 0.01x | 2.58x | $-9.08 Million |
| 2024 | 0.00% | -3131.18% | 0.02x | 0.00x | $-4.21 Million |
Industry Comparison
This section compares Celyad Oncology SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celyad Oncology SA (CLYYF) | $-3.10 Million | -77.22% | N/A | $6.71 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |